Neurobiological mechanisms of ECT and TMS treatment in depression : study protocol of a multimodal magnetic resonance investigation
(2023) In BMC Psychiatry 23(1).- Abstract
Background: Noninvasive neurostimulation treatments are increasingly being used to treat major depression, which is a common cause of disability worldwide. While electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are both effective in treating depressive episodes, their mechanisms of action are, however, not completely understood. ECT is given under general anesthesia, where an electrical pulse is administered through electrodes placed on the patient’s head to trigger a seizure. ECT is used for the most severe cases of depression and is usually not prescribed before other options have failed. With TMS, brain stimulation is achieved through rapidly changing magnetic fields that induce electric currents underneath... (More)
Background: Noninvasive neurostimulation treatments are increasingly being used to treat major depression, which is a common cause of disability worldwide. While electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are both effective in treating depressive episodes, their mechanisms of action are, however, not completely understood. ECT is given under general anesthesia, where an electrical pulse is administered through electrodes placed on the patient’s head to trigger a seizure. ECT is used for the most severe cases of depression and is usually not prescribed before other options have failed. With TMS, brain stimulation is achieved through rapidly changing magnetic fields that induce electric currents underneath a ferromagnetic coil. Its efficacy in depressive episodes has been well documented. This project aims to identify the neurobiological underpinnings of both the effects and side effects of the neurostimulation techniques ECT and TMS. Methods: The study will utilize a pre-post case control longitudinal design. The sample will consist of 150 subjects: 100 patients (bipolar and major depressive disorder) who are treated with either ECT (N = 50) or TMS (N = 50) and matched healthy controls (N = 50) not receiving any treatment. All participants will undergo multimodal magnetic resonance imaging (MRI) as well as neuropsychological and clinical assessments at multiple time points before, during and after treatment. Arterial spin labeling MRI at baseline will be used to test whether brain perfusion can predict outcomes. Signs of brain disruption, potentiation and rewiring will be explored with resting-state functional MRI, magnetic resonance spectroscopy and multishell diffusion weighted imaging (DWI). Clinical outcome will be measured by clinician assessed and patient reported outcome measures. Memory-related side effects will be investigated, and specific tests of spatial navigation to test hippocampal function will be administered both before and after treatment. Blood samples will be stored in a biobank for future analyses. The observation time is 6 months. Data will be explored in light of the recently proposed disrupt, potentiate and rewire (DPR) hypothesis. Discussion: The study will contribute data and novel analyses important for our understanding of neurostimulation as well as for the development of enhanced and more personalized treatment. Trial registration: ClinicalTrials.gov Identifier: NCT05135897.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cognitive deficits, Electroconvulsive therapy, Magnetic resonance imaging, Major depressive disorder, Transcranial magnetic stimulation
- in
- BMC Psychiatry
- volume
- 23
- issue
- 1
- article number
- 791
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:37904091
- scopus:85175592603
- ISSN
- 1471-244X
- DOI
- 10.1186/s12888-023-05239-0
- language
- English
- LU publication?
- yes
- id
- 229fc73b-f019-438b-a3ee-952c2007686f
- date added to LUP
- 2023-11-24 14:04:28
- date last changed
- 2024-04-21 16:55:43
@article{229fc73b-f019-438b-a3ee-952c2007686f,
abstract = {{<p>Background: Noninvasive neurostimulation treatments are increasingly being used to treat major depression, which is a common cause of disability worldwide. While electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are both effective in treating depressive episodes, their mechanisms of action are, however, not completely understood. ECT is given under general anesthesia, where an electrical pulse is administered through electrodes placed on the patient’s head to trigger a seizure. ECT is used for the most severe cases of depression and is usually not prescribed before other options have failed. With TMS, brain stimulation is achieved through rapidly changing magnetic fields that induce electric currents underneath a ferromagnetic coil. Its efficacy in depressive episodes has been well documented. This project aims to identify the neurobiological underpinnings of both the effects and side effects of the neurostimulation techniques ECT and TMS. Methods: The study will utilize a pre-post case control longitudinal design. The sample will consist of 150 subjects: 100 patients (bipolar and major depressive disorder) who are treated with either ECT (N = 50) or TMS (N = 50) and matched healthy controls (N = 50) not receiving any treatment. All participants will undergo multimodal magnetic resonance imaging (MRI) as well as neuropsychological and clinical assessments at multiple time points before, during and after treatment. Arterial spin labeling MRI at baseline will be used to test whether brain perfusion can predict outcomes. Signs of brain disruption, potentiation and rewiring will be explored with resting-state functional MRI, magnetic resonance spectroscopy and multishell diffusion weighted imaging (DWI). Clinical outcome will be measured by clinician assessed and patient reported outcome measures. Memory-related side effects will be investigated, and specific tests of spatial navigation to test hippocampal function will be administered both before and after treatment. Blood samples will be stored in a biobank for future analyses. The observation time is 6 months. Data will be explored in light of the recently proposed disrupt, potentiate and rewire (DPR) hypothesis. Discussion: The study will contribute data and novel analyses important for our understanding of neurostimulation as well as for the development of enhanced and more personalized treatment. Trial registration: ClinicalTrials.gov Identifier: NCT05135897.</p>}},
author = {{Frid, Leila Marie and Kessler, Ute and Ousdal, Olga Therese and Hammar, Åsa and Haavik, Jan and Riemer, Frank and Hirnstein, Marco and Ersland, Lars and Erchinger, Vera Jane and Ronold, Eivind Haga and Nygaard, Gyrid and Jakobsen, Petter and Craven, Alexander R. and Osnes, Berge and Alisauskiene, Renata and Bartsch, Hauke and Le Hellard, Stephanie and Stavrum, Anne Kristin and Oedegaard, Ketil J. and Oltedal, Leif}},
issn = {{1471-244X}},
keywords = {{Cognitive deficits; Electroconvulsive therapy; Magnetic resonance imaging; Major depressive disorder; Transcranial magnetic stimulation}},
language = {{eng}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Psychiatry}},
title = {{Neurobiological mechanisms of ECT and TMS treatment in depression : study protocol of a multimodal magnetic resonance investigation}},
url = {{http://dx.doi.org/10.1186/s12888-023-05239-0}},
doi = {{10.1186/s12888-023-05239-0}},
volume = {{23}},
year = {{2023}},
}